Full metadata record
DC Field | Value | Language |
---|---|---|
dc.creator | Melero, I. (Ignacio) | - |
dc.creator | Duarte, M. (Marina) | - |
dc.creator | Ruiz, J. (Juan) | - |
dc.creator | Sangro, B. (Bruno) | - |
dc.creator | Galofre, J.C. (Juan Carlos) | - |
dc.creator | Mazzolini, G. (Guillermo) | - |
dc.creator | Bustos, M. (Matilde) | - |
dc.creator | Qian, C. (Cheng) | - |
dc.creator | Prieto, J. (Jesús) | - |
dc.date.accessioned | 2012-04-23T13:04:36Z | - |
dc.date.available | 2012-04-23T13:04:36Z | - |
dc.date.issued | 1999 | - |
dc.identifier.citation | Melero I, Duarte M, Ruiz J, Sangro B, Galofre J, Mazzolini G, et al. Intratumoral injection of bone-marrow derived dendritic cells engineered to produce interleukin-12 induces complete regression of established murine transplantable colon adenocarcinomas. Gene Ther 1999 Oct;6(10):1779-1784. | es_ES |
dc.identifier.issn | 1476-5462 | - |
dc.identifier.uri | https://hdl.handle.net/10171/21741 | - |
dc.description.abstract | Stimulation of the antitumor immune response by dendritic cells (DC) is critically dependent on their tightly regulated ability to produce interleukin-12 (IL-12). To enhance this effect artificially, bone marrow (BM)-derived DC were genetically engineered to produce high levels of functional IL-12 by ex vivo infection with a recombinant defective adenovirus (AdCMVIL-12). DC-expressing IL-12 injected into the malignant tissue eradicated 50-100% well established malignant nodules derived from the injection of two murine colon adenocarcinoma cell lines. Successful therapy was dependent on IL-12 transfection and was mediated only by syngeneic, but not allogeneic BM-derived DC, indicating that compatible antigen-presenting molecules were required. The antitumor effect was inhibited by in vivo depletion of CD8+ T cells and completely abrogated by simultaneous depletion with anti-CD4 and anti-CD8 mAbs. Mice which had undergone tumor regression remained immune to a rechallenge with tumor cells, showing the achievement of long-lasting systemic immunity that also was able to reject simultaneously induced concomitant untreated tumors. Tumor regression was associated with a detectable CTL response directed against tumor-specific antigens probably captured by DC artificially released inside tumor nodules. Our results open the possibility of similarly treating the corresponding human malignancies. | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Nature Publishing Group | es_ES |
dc.rights | info:eu-repo/semantics/openAccess | es_ES |
dc.subject | Dendritic cell | es_ES |
dc.subject | Interleukin-12 | es_ES |
dc.subject | Colon cancer | es_ES |
dc.subject | Adenovirus | es_ES |
dc.subject | CTLs | es_ES |
dc.title | Intratumoral injection of bone-marrow derived dendritic cells engineered to produce interleukin-12 induces complete regression of established murine transplantable colon adenocarcinomas | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.relation.publisherversion | http://www.nature.com/gt/journal/v6/n10/full/3301010a.html | es_ES |
dc.type.driver | info:eu-repo/semantics/article | es_ES |
Files in This Item:
Statistics and impact
Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.